Shrimp’s Disease Treatment Market Size, Share, and Growth Forecast 2026 - 2033

The global shrimp’s disease treatment market size is likely to be valued at US$2.4 billion in 2026 and is estimated to reach US$4.8 billion by 2033, growing at a CAGR of 10.7% during the forecast period from 2026 to 2033, driven by the rising frequency of bacterial, viral, and parasitic diseases in intensive shrimp farms. Surging adoption of probiotics, phytobiotics, immunostimulants, and rapid diagnostic tools is also encouraging farmers to invest in preventive disease management.

Driver - Disease Outbreaks to Push Farmers toward Quick Health Interventions

Disease outbreaks create massive production losses and can spread quickly between connected ponds. This makes early detection, biosecurity, and treatment very important. WSSV remains a major concern as infection can progress rapidly, while AHPND is linked to pathogenic Vibrio parahaemolyticus. Research published in 2025 showed that higher shrimp stocking density can accelerate WSSV viral shedding and mortality. This strengthens the case for routine testing and preventive health management.

India provides a key example. ICAR-CIBA estimates that EHP creates major annual economic losses for the country's shrimp sector. In 2025, the institute transferred its EHP treatment technology to a private aquaculture company after field validation. Such developments show that disease losses are encouraging farmers and suppliers to move from reactive treatment toward regular monitoring and preventive products.

Rising Demand for Clean Shrimp to Boost the Use of Non-antibiotic Solutions

Growing concern about antimicrobial resistance and residues is encouraging shrimp producers to adopt probiotics, phytobiotics, immunostimulants, and functional feeds. This shift is particularly important for export-oriented farms as residue compliance can affect access to international markets. In India, ICAR conducted farmer programs in 2025 specifically addressing antimicrobial resistance and antibiotic residues in shrimp aquaculture.

Commercial companies are responding with non-antibiotic solutions. Skretting promotes probiotics for shrimp health and water management, while dsm-firmenich uses pathogen-control approaches that include competitive exclusion and probiotic technologies. Recent research also shows surging interest in synbiotics, with a 2025 study reporting improved shrimp immunity against AHPND in a biofloc system supplemented with synbiotics.

Restraint - Shortages and Supply Risks May Slow Access to Advanced Disease-control Products

The shrimp-health industry now relies on specialized diagnostic reagents, microbial strains, enzymes, biologically active compounds, and other temperature-sensitive or technically demanding inputs. Interruptions in these supply chains can delay testing or product availability. This is more difficult for small-scale farms that depend on regional distributors rather than maintaining their own laboratory infrastructure.

The problem is especially relevant for advanced diagnostics, as conventional EHP testing can require laboratory equipment and sample transport. Thailand's 2026 rapid EHP test was developed partly to overcome this delay, replacing a process that could take two to three days with an on-site test taking about 25 minutes. Geopolitical disruptions and raw-material volatility can further affect international procurement. These pressures encourage local manufacturing and simple field-based diagnostics, but developing reliable alternatives still requires validation and regulatory approval.

Opportunity - Natural Compounds to Offer Safe Alternatives for Disease Management

Plant extracts, phytobiotics, and other natural compounds are gaining momentum as they can support disease control without relying entirely on conventional antibiotics. ICAR-CIBA's CIBA EHP Cura Gro Plus is a leading example. The phytobiotic product was developed after seven years of research and was field-validated across several Indian shrimp-producing states. ICAR reported effects on EHP proliferation, Vibrio load, and shrimp health.

Research is also examining compounds that stimulate shrimp immunity rather than directly killing pathogens. A 2025 study found that dietary dextran sulfate and heparin increased immune-related responses in whiteleg shrimp and provided partial protection against WSSV challenge. These approaches are projected to support the development of feed-based disease-management products.

Probiotics to Improve Shrimp Resilience While Reducing Antibiotic Dependence

Probiotics offer an opportunity as they can act on both shrimp health and the pond environment. Beneficial microbes can compete with pathogens, modify gut microbiota, and improve water conditions. A 2026 review identified probiotics as one of the main biological-control approaches being developed for shrimp disease, alongside bacteriophages, biofloc, and other ecological methods.

Commercial adoption is already visible. Skretting promotes probiotic applications for shrimp gut and pond management, while BioMar incorporates probiotic Bactocell and yeast-derived ingredients into shrimp starter feeds. A 2025 study also found that synbiotic supplementation in biofloc systems improved P. vannamei immunity against AHPND.

Treatment Type Insights

Antibiotics are predicted to lead with a share of about 45.6% in 2026, as bacterial diseases such as AHPND and Vibrio-associated infections can cause rapid mortality and have historically been managed with antibacterial products, giving antibiotics a practical role where a bacterial cause is confirmed. Another factor is that antibiotic-based products fit established farm practices as they can be incorporated into medicated feeds and delivered across large shrimp populations.

Probiotics are likely to remain in the second position in 2026, as they help manage disease pressure without relying on antibiotics. In shrimp farming, probiotic microorganisms can improve gut health, compete with pathogens such as Vibrio for nutrients and attachment sites, produce antimicrobial compounds, and stimulate innate immune responses. Their relevance is strong for diseases such as AHPND and vibriosis, where maintaining a stable microbial environment can help reduce pathogen proliferation.

End-User Insights

Aquaculture farms are anticipated to dominate with a share of around 52.5% in 2026, as disease outbreaks mainly affect survival, feed efficiency, growth, and harvest quality. It is making farms the point where diagnostics, probiotics, functional feeds, biosecurity products, and therapeutics are ultimately applied.

Research laboratories are expected to be the fastest-growing application over the forecast period, as the market needs new solutions for diseases that lack effective cures, leading to greater work on RNAi, vaccines, molecular diagnostics, probiotics, phytobiotics, host immunity, and pathogen biology. The USDA, for example, began a 2025-2030 research project specifically focused on reducing disease losses in crustacean aquaculture.

Asia Pacific Shrimp’s Disease Treatment Market Trends

Asia Pacific is anticipated to dominate globally in 2026 with a share of around 40.8%, as it combines the world's largest concentration of aquaculture production with extensive shrimp farming and frequent exposure to pathogens such as WSSV, AHPND, and EHP. FAO reported in 2026 that Asia accounted for 76% of global aquatic-animal and algae production in 2024, with aquaculture responsible for a large share of regional output. Disease-control needs are exponential as producers are moving toward more intensive farming. High stocking densities can accelerate WSSV progression and viral shedding, increasing the value of early diagnostics and preventive health measures.

China Shrimp’s Disease Treatment Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 33.7%, as its huge aquaculture base creates a large application pool for shrimp health products. Domestic research is focused on disease surveillance, molecular mechanisms, and intensive farming systems. FAO reported that China produced 57.6 million tons of farmed aquatic animals in 2024, the largest national contribution to Asia's aquaculture output. Local research is also addressing emerging shrimp diseases. A 2025 Aquaculture study examined the molecular mechanism of White Syndrome in Macrobrachium rosenbergii and identified candidate genes that could support future disease-management research.

India Shrimp’s Disease Treatment Market Trends

In 2026, India is projected to account for a share of just about 21.8% in Asia Pacific, as it has a large export-oriented shrimp industry and is facing significant pressure from EHP, WSSV, WFS, and other health problems. ICAR-CIBA estimated that EHP-related losses alone impose substantial economic pressure on Indian shrimp farmers. This has encouraged domestic development of phytobiotics, diagnostics, and disease-management technologies. India is also moving technologies closer to farms. In 2025, ICAR-CIBA transferred its EHP treatment technology to V.K. Aqua Feeds, while in 2026 the institute worked on pond-side EHP detection and farmer-level disease surveillance.

North America Shrimp’s Disease Treatment Market Trends

North America is predicted to be the fastest-growing market, due to strong aquatic-animal health infrastructure, advanced diagnostic capabilities, university research, biotechnology investment, and stringent disease surveillance, creating demand for high-value disease-management technologies. USDA's aquaculture health system includes standardized testing, surveillance, biosecurity, and disease-response infrastructure, while USDA researchers are actively studying WSSV and Vibrio diseases in shrimp.

The region also has a strong demand for pathogen-control technologies as the U.S. imports large volumes of shrimp and faces risks from transboundary movement of shrimp pathogens. U.S. authorities have specifically identified live and imported shrimp as potential pathways for pathogen introduction.

U.S. Shrimp’s Disease Treatment Market Trends

A share of nearly 65.3% is expected to be held by the U.S. in 2026 in North America, as government research is moving beyond basic surveillance toward practical disease-control technologies. The USDA's 2025-2030 crustacean research program covers WSSV diagnostics, Vibrio control, and bioactive compounds that could protect shrimp from bacterial disease. The country's highly developed laboratory network also supports demand for disease testing. APHIS maintains approved laboratories and a National Animal Health Laboratory Network for disease surveillance and outbreak response.

Europe Shrimp’s Disease Treatment Market Trends

Europe will likely see steady growth over the forecast period with a share of roughly 16.5% in 2026 globally, as shrimp farming remains relatively small, but interest in controlled indoor and intensive production is increasing. This is augmenting demand for technologies that can manage disease in high-density systems. The EU policy also places greater emphasis on disease prevention, surveillance, and animal health. The European Commission further updated aquatic-disease measures in 2025 and maintains specific disease categories for crustaceans, including Taura syndrome virus, yellow head virus, and WSSV.

Germany Shrimp’s Disease Treatment Market Trends

Germany is predicted to register a substantial share of approximately 37.2% in 2026 in Europe. Its opportunity is linked more to research, technology, and controlled aquaculture than to large-scale shrimp production. European disease-management requirements and Germany's established aquatic-health research capabilities support interest in diagnostics, monitoring, and biosecurity. Climate-related changes are also relevant as local authorities note that warm water can favor pathogens such as Vibrio and increase their importance in seafood as well as aquatic systems.

U.K. Shrimp’s Disease Treatment Market Trends

A share of nearly 22.6% is predicted to be held by the U.K. in 2026 in Europe. It has a stronger research and regulatory role than a large commercial shrimp-farming role. Institutions such as Cefas maintain aquatic pathology capabilities, while British research contributes to understanding shrimp pathogens and aquaculture biosecurity. As interest in indoor shrimp farming grows, U.K. expertise in aquatic disease surveillance and diagnostics can support the development of high-value disease-management solutions.

The global shrimp’s disease treatment market is fragmented and shifting from conventional therapeutics toward integrated disease prevention, diagnostics, probiotics, phytobiotics, immunostimulants, and emerging vaccines. The market has no single company controlling the full disease-management chain. Instead, feed and aquaculture-health companies compete with specialist diagnostic firms, biotechnology companies, research institutes, and shrimp producers that develop their own health-management systems.

Companies such as Benchmark Holdings through INVE Aquaculture, dsm-firmenich, BioMar, Skretting, Phibro Animal Health, Kemin Industries, and ADM have developed products aimed at gut health, pathogen control, immunity, water quality, or disease resistance rather than relying only on direct drug treatment. A major competitive shift is occurring as many important shrimp diseases do not have a simple curative drug.

Key Industry Developments:

• In April 2026, DTU Aqua and Danish start-up Sincere Aqua began developing the Sincere Shrimp Disease Detector. The system uses underwater cameras and artificial intelligence to identify early behavioral and visual signs of disease in warm-water shrimp. White spot disease is being used as the initial test case, with the aim of creating continuous disease monitoring for intensive shrimp farms.
• In January 2026, Thailand's BIOTEC and NSTDA launched a 25-minute on-site diagnostic kit for EHP. The agency reported that the test showed 100% accuracy correlation with qPCR in symptomatic shrimp during validation. The technology was licensed to Marine Leader Co. for international commercialization, giving farmers a faster alternative to laboratory-based EHP testing.
• In January 2026, Yuyu Pharma announced a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company developing an innate-immunity platform for vaccines for shrimp and other animals. Dalan also announced a US$3 million seed financing round to advance commercialization of its shrimp vaccine technology. The company is targeting major shrimp diseases, including white spot syndrome virus, creating a new vaccine-focused route for disease prevention.